Harrison W. Farber, MD
Professor of Medicine
Director, Pulmonary Hypertension Center
Boston University School of Medicine
Robyn J. Barst, MD
Professor of Pediatrics, Pediatrics-Cardiology
New York Presbyterian Hospital at Columbia University
New York, NY
Adaani Frost, MD
Professor of Medicine - Pulmonary
Baylor College of Medicine
Farnaz Pezeshki, PharmD
Boston Medical Center
Associate Adjunct Faculty
Massachusetts College of Pharmacy and Health Science
Pulmonary arterial hypertension (PAH) is an obstructive disorder characterized by a progressive remodeling of small pulmonary arteries leading to elevated pulmonary vascular resistance and right ventricular failure, eventually culminating in death. Although PAH cannot be cured, many treatment modalities have been developed that improve survival and quality of life for PAH patients. However, in order to optimize patient outcomes, providers should be aware of the potential toxicities and drug-drug interactions between individual PAH-specific agents as well as between PAH specific and non-PAH medications.
This continuing medical education activity, Managing Patients with PAH: What You Need to Know About Drug-Drug Interactions, presents case-study vignettes supplemented with expert commentary that illustrate the safest medication regimen for specific patients based on their medical history and current medications. In addition, this program provides a summary of known and clinically relevant drug-drug interactions between PAH and non-PAH agents, which can assist providers in designing the safest and most effective management strategies for their patients with PAH.
Physicians and physician assistants in the United States involved in the care of patients with PAH.
After completing this educational activity, participants will be better able to:
· Recognize the potential for dangerous drug-drug interactions among agents prescribed to patients with PAH
· Individualize treatment regimens for patients receiving PAH/non-PAH agents to minimize the risk of clinically relevant drug-drug interactions
· Discuss the possibility of drug-drug interactions between PAH and non-PAH drugs with patients and monitor for emergence of those interactions
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of the University of Kentucky College of Medicine and HealthmattersCME. The University of Kentucky College of Medicine is accredited by the ACCME to provide continuing medical education for physicians.
The University of Kentucky College of Medicine designates this educational activity for a maximum of 1.0 AMA PRA Category 1CreditsTM. Physicians should only claim credit commensurate with the extent of their participation in the activity. The University of Kentucky College of Medicine presents this activity for educational purposes only. Participants are expected to utilize their own expertise and judgment while engaged in the practice of medicine. The content of the presentations is provided solely by presenters who have been selected for presentations because of recognized expertise in their field.
The University of Kentucky is an equal opportunity university.
Disclosure of Financial Interest Summary
In accordance with policies set forth by the ACCME and the Accreditation Council for Pharmacy Education (ACPE), University of Kentucky UK HealthCare CECentral (UKHCCEC) requires all faculty members and spouses/significant others with an opportunity to affect the content of a continuing education activity to disclose any relevant financial relationships during the past 12 months with commercial interests. A commercial interest is any entity producing, marketing, reselling, or distributing health care goods or services consumed by or used on patients. Relationships with commercial interests and conflicts of interest resulting from those relationships must be revealed to the audience and resolved prior to the activity.
Relevant relationships include roles such as speaker, author, consultant, independent contractor (including research), employee, investor, advisory committee member, board member, review panelist, and investigator. If a potential speaker or author indicates a possible conflict of interest, the conflict will be resolved by choosing another speaker or author for that topical area, or the slides, handouts, and/or monograph will be reviewed and approved by a qualified commercially disinterested peer.
Disclosure of a relationship is not intended to suggest or condone any bias in any presentation, but is made to provide participants with information that might be of potential importance to their evaluation of a presentation.
Harrison Farber, MD
Speaker/Consultant: Actelion Pharmaceuticals, Gilead Sciences, Inc, United Therapeutics
Robyn J. Barst, MD
Consultant: Actelion Pharmaceuticals, Bayer, Eli Lilly and Company, Gilead Sciences, Inc, GlaxoSmithKline, Novartis, Pfizer
Adaani Frost, MD
PI and CO-I FDA/IRB approved multicenter studies on PH: Actelion Pharmaceuticals, Eli Lilly and Company, Gilead Sciences, Inc, Novartis, Pfizer
Consultant/Advisory Board Committee Member: Gilead Sciences, Inc
Farnaz Pezeshki, PharmD has no real or apparent conlicts of interest to report.